FIGURE 3.

Stem cell‐like (SCL) cell derived DU145 lineages display sensitivity to the combined docetaxel/fenofibrate (DCX/FF) treatment. A, Motility of naïve DU145 and DU145_DCX20 cells, and their counterparts derived from naive and DCX‐treated SCL cells (nSCL_ and dcxSCL, respectively) was estimated with time‐lapse videomicroscopy immediately after the administration of DCX and/or FF (10 nM/25 μM). B, Cells were treated with DCX and/or FF as in A and counted with Coulter counter after 48 hours. C, The architecture of microtubular cytoskeleton was estimated with immunofluorescence after 48 hours of DCX/FF treatment along with calcein efflux assay (lower panel; cf. Figure 1G). D, Cells were treated with DCX/FF for 48 hours and their morphology/actin cytoskeleton architecture was visualized with immunofluorescence. Time‐lapse videomicroscopy was employed to assess long‐term (48 hours) effects of FF, DCX and DCX/FF on cell motility (lower panel). E, Cells were DCX/FF treated for 72 hours and their apoptotic response was estimated by annexinV/PI assay. Compensated dot‐plots comprise 30 000/50 000 events, classified based on their bright‐field ratios and/or nuclear contrast. Scale bars = 50 μm. D, The statistical significance of the differences was tested with t‐Student test (B, C, E; #P ≤ .05 vs untreated control; *P ≤ .05 vs wild‐type [WT] lineage or selected bars) or by one‐way ANOVA followed by post hoc Tukey's HSD (A, D; *P ≤ .05 vs WT lineage or selected bars/points). Note the sensitivity of SCL‐derived lineages to the combined DCX/FF‐treatment